Champions Oncology, Inc.(CSBR)Earnings, Financials & Key Ratios
CSBR•NASDAQ
$5.99
$84M mkt cap·18.2× P/E·Price updated May 7, 2026
AboutChampions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.Show more
- Revenue$57M+13.5%
- EBITDA$6M+228.3%
- Net Income$5M+164.6%
- EPS (Diluted)0.33+161.1%
- Gross Margin47.27%+14.2%
- EBITDA Margin11.39%+213.0%
- Operating Margin8.51%+161.7%
- Net Margin8.26%+156.9%
- ROE503.05%+194.5%
- ROIC242.22%+240.6%
- Debt/Equity1.62
- Interest Coverage179.48+172.6%
CSBR Key Insights
Champions Oncology, Inc. (CSBR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 12.1%
- ✓Efficient asset utilization: 1.8x turnover
✗Weaknesses
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 22.7x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CSBR Price & Volume
Champions Oncology, Inc. (CSBR) stock price & volume — 10-year historical chart
Loading chart...
CSBR Growth Metrics
Champions Oncology, Inc. (CSBR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years20.44%
5 Years12.13%
3 Years5.06%
TTM-29.37%
Profit CAGR
10 Years-
5 Years-
3 Years104.71%
TTM-135.01%
EPS CAGR
10 Years-
5 Years-
3 Years104.3%
TTM-136.46%
Return on Capital
10 Years-182.81%
5 Years-5.85%
3 Years-11.91%
Last Year74.09%
CSBR Peer Comparison
Champions Oncology, Inc. (CSBR) competitors in Biopharma Services and CROs — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.53B | 27.22 | -9.97 | -47.07% | 0.00 | |||
 CASI | 2.33M | 0.15 | -0.06 | -15.77% | -183.93% | -301.8% | 11.96 | |
 TPVG | 242.54M | 5.99 | 4.91 | 36.55% | -3.39% | 1.33 | ||
 IDXX | 45.45B | 572.20 | 43.75 | 10.42% | 24.63% | 70.87% | 0.67 | |
 NTRA | 31.16B | 219.82 | -144.62 | 35.9% | -9.03% | -15.28% | 0.13 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 AGEN | 132.45M | 3.75 | -1102.94 | 10.37% | 0.1% | |||
 CRL | 8.98B | 181.94 | -62.52 | -0.85% | -4.59% | -5.68% | 0.95 |
Compare CSBR vs Peers
Champions Oncology, Inc. (CSBR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CSBR Income Statement
Champions Oncology, Inc. (CSBR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Apr'17 | Apr'18 | Apr'19 | Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | Apr'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 15.41M | 20.24M | 27.07M | 32.12M | 41.04M | 49.11M | 53.87M | 50.16M | 56.94M | 41.38M |
| Revenue Growth % | 37.82% | 31.34% | 33.72% | 18.68% | 27.76% | 19.66% | 9.69% | -6.9% | 13.54% | -29.37% |
| Cost of Goods Sold | 9.7M | 10.55M | 14.27M | 17M | 21.45M | 23.63M | 29.53M | 29.4M | 30.03M | 32.47M |
| COGS % of Revenue | 62.96% | 52.14% | 52.7% | 52.92% | 52.26% | 48.12% | 54.82% | 58.62% | 52.73% | - |
| Gross Profit | 5.71M▲ 0% | 9.69M▲ 69.7% | 12.8M▲ 32.1% | 15.12M▲ 18.1% | 19.59M▲ 29.6% | 25.48M▲ 30.0% | 24.34M▼ 4.5% | 20.75M▼ 14.7% | 26.91M▲ 29.7% | 8.91M▲ 0% |
| Gross Margin % | 37.04% | 47.86% | 47.3% | 47.08% | 47.74% | 51.88% | 45.18% | 41.38% | 47.27% | 21.54% |
| Gross Profit Growth % | 128.69% | 69.73% | 32.14% | 18.13% | 29.56% | 30.02% | -4.47% | -14.73% | 29.69% | - |
| Operating Expenses | 12.52M | 11.04M | 12.53M | 16.71M | 19.23M | 24.87M | 28.79M | 27.68M | 22.07M | 27.79M |
| OpEx % of Revenue | 81.22% | 54.55% | 46.3% | 52.02% | 46.85% | 50.64% | 53.44% | 55.18% | 38.76% | - |
| Selling, General & Admin | 8.22M | 6.64M | 7.73M | 10.86M | 12.03M | 15.5M | 17.24M | 18.13M | 15.24M | 19.12M |
| SG&A % of Revenue | 53.36% | 32.81% | 28.57% | 33.8% | 29.32% | 31.55% | 32.01% | 36.15% | 26.77% | - |
| Research & Development | 4.29M | 4.4M | 4.8M | 5.85M | 7.2M | 9.37M | 11.54M | 9.54M | 6.83M | 8.93M |
| R&D % of Revenue | 27.86% | 21.74% | 17.73% | 18.22% | 17.53% | 19.09% | 21.43% | 19.03% | 11.99% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -268K |
| Operating Income | -6.81M▲ 0% | -1.35M▲ 80.1% | 270K▲ 119.9% | -1.59M▼ 687.4% | 366K▲ 123.1% | 607K▲ 65.8% | -4.45M▼ 832.9% | -6.92M▼ 55.6% | 4.85M▲ 170.0% | -2.31M▲ 0% |
| Operating Margin % | -44.18% | -6.69% | 1% | -4.94% | 0.89% | 1.24% | -8.26% | -13.8% | 8.51% | -5.59% |
| Operating Income Growth % | 34% | 80.11% | 119.94% | -687.41% | 123.08% | 65.85% | -832.95% | -55.56% | 170.02% | - |
| EBITDA | -6.64M | -994K | 876K | -358K | 1.95M | 3.02M | -1.25M | -5.05M | 6.49M | -1.2M |
| EBITDA Margin % | -43.09% | -4.91% | 3.24% | -1.11% | 4.75% | 6.15% | -2.32% | -10.08% | 11.39% | -2.91% |
| EBITDA Growth % | 34.64% | 85.03% | 188.13% | -140.87% | 644.13% | 55.03% | -141.42% | -304% | 228.33% | -114.28% |
| D&A (Non-Cash Add-back) | 168K | 360K | 606K | 1.23M | 1.58M | 2.41M | 3.2M | 1.87M | 1.64M | 1.11M |
| EBIT | -6.87M | -1.44M | 231K | -1.96M | 437K | 583K | -5.27M | -7.28M | 4.65M | -2.16M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | -24K | 0 | 64K | 60K | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 92K | 87K | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 24K | 0 | 28K | 27K | 0 |
| Other Income/Expense | -56K | -89K | -39K | -377K | 71K | -24K | -818K | -387K | -220K | -86K |
| Pretax Income | -6.87M▲ 0% | -1.44M▲ 79.0% | 231K▲ 116.0% | -1.96M▼ 949.8% | 437K▲ 122.3% | 583K▲ 33.4% | -5.27M▼ 1003.4% | -7.31M▼ 38.8% | 4.63M▲ 163.3% | -2.4M▲ 0% |
| Pretax Margin % | -44.55% | -7.12% | 0.85% | -6.11% | 1.06% | 1.19% | -9.78% | -14.57% | 8.12% | -5.79% |
| Income Tax | 19K | 33K | 103K | 130K | 75K | 35K | 68K | -32K | -75K | -55K |
| Effective Tax Rate % | -0.28% | -2.29% | 44.59% | -6.62% | 17.16% | 6% | -1.29% | 0.44% | -1.62% | 2.29% |
| Net Income | -6.88M▲ 0% | -1.48M▲ 78.6% | 128K▲ 108.7% | -2.09M▼ 1735.2% | 362K▲ 117.3% | 548K▲ 51.4% | -5.33M▼ 1073.5% | -7.28M▼ 36.4% | 4.7M▲ 164.6% | -2.25M▲ 0% |
| Net Margin % | -44.67% | -7.29% | 0.47% | -6.52% | 0.88% | 1.12% | -9.9% | -14.51% | 8.26% | -5.44% |
| Net Income Growth % | 34.1% | 78.56% | 108.67% | -1735.16% | 117.3% | 51.38% | -1073.54% | -36.38% | 164.61% | -135.01% |
| Net Income (Continuing) | -6.88M | -1.48M | 128K | -2.09M | 362K | 548K | -5.33M | -7.28M | 4.7M | -2.34M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 95K |
| EPS (Diluted) | -0.63▲ 0% | -0.13▲ 79.4% | 0.01▲ 107.0% | -0.18▼ 2078.0% | 0.02▲ 113.8% | 0.04▲ 56.0% | -0.39▼ 1107.8% | -0.54▼ 38.5% | 0.33▲ 161.1% | -0.16▲ 0% |
| EPS Growth % | 47.5% | 79.37% | 107% | - | 113.78% | 56.05% | -1107.75% | -38.46% | 161.11% | -136.46% |
| EPS (Basic) | -0.64 | -0.13 | 0.01 | -0.18 | 0.03 | 0.04 | -0.39 | -0.54 | 0.34 | - |
| Diluted Shares Outstanding | 10.98M | 11M | 14.1M | 11.84M | 14.57M | 14.16M | 13.54M | 13.55M | 14.27M | 13.89M |
| Basic Shares Outstanding | 10.68M | 10.99M | 11.34M | 11.84M | 13.14M | 13.2M | 13.54M | 13.55M | 13.66M | 13.89M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CSBR Balance Sheet
Champions Oncology, Inc. (CSBR) balance sheet — assets, liabilities & shareholders' equity
| Line item | Apr'17 | Apr'18 | Apr'19 | Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | Apr'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 5.87M | 5.06M | 7.92M | 13.5M | 12.63M | 19.66M | 19.46M | 13.64M | 22.37M | 20.18M |
| Cash & Short-Term Investments | 3.29M | 856K | 3.24M | 8.34M | 4.69M | 9.01M | 10.12M | 2.62M | 9.79M | 7.13M |
| Cash Only | 3.29M | 856K | 3.24M | 8.34M | 4.69M | 9.01M | 10.12M | 2.62M | 9.79M | 7.13M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 2.27M | 3.92M | 4.38M | 4.77M | 6.99M | 9.51M | 8.01M | 9.53M | 11.23M | 12.07M |
| Days Sales Outstanding | 53.86 | 70.63 | 59.02 | 54.2 | 62.13 | 70.7 | 54.28 | 69.32 | 72.01 | 97.71 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 1.33M | 1.5M | 1.35M | 991K |
| Total Non-Current Assets | 2.14M | 3.02M | 3.34M | 7.25M | 14.96M | 15.71M | 14.85M | 12.49M | 9.97M | 8.26M |
| Property, Plant & Equipment | 1.22M | 2.08M | 2.55M | 6.79M | 14.61M | 15.36M | 14.5M | 11.97M | 9.46M | 9.26M |
| Fixed Asset Turnover | 12.67x | 9.72x | 10.63x | 4.73x | 2.81x | 3.20x | 3.71x | 4.19x | 6.02x | 4.60x |
| Goodwill | 669K | 669K | 669K | 335K | 335K | 335K | 335K | 335K | 335K | 335K |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | -21.82M | 150K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 257K | 266K | 128K | 128K | 15K | 15K | 15K | 185K | 185K | -756K |
| Total Assets | 8.01M▲ 0% | 8.08M▲ 0.8% | 11.27M▲ 39.5% | 20.75M▲ 84.2% | 27.59M▲ 33.0% | 35.38M▲ 28.2% | 34.31M▼ 3.0% | 26.13M▼ 23.8% | 32.34M▲ 23.8% | 28.45M▲ 0% |
| Asset Turnover | 1.92x | 2.51x | 2.40x | 1.55x | 1.49x | 1.39x | 1.57x | 1.92x | 1.76x | 1.36x |
| Asset Growth % | 38.67% | 0.84% | 39.45% | 84.21% | 32.96% | 28.22% | -3.02% | -23.84% | 23.77% | 58.67% |
| Total Current Liabilities | 7.45M | 7.48M | 8.03M | 12.3M | 11.2M | 17.48M | 21.73M | 21.54M | 23.85M | 20.68M |
| Accounts Payable | 1.85M | 2.15M | 2.81M | 3.14M | 1.89M | 2.87M | 5.33M | 5.8M | 4.25M | 0 |
| Days Payables Outstanding | 69.67 | 74.5 | 71.82 | 67.42 | 32.23 | 44.3 | 65.93 | 72 | 51.63 | 42.39 |
| Short-Term Debt | 25K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 4.91M | 4.7M | 4.02M | 5.82M | 6.26M | 11.07M | 12.78M | 12.09M | 15.44M | 52.21M |
| Other Current Liabilities | -25K | 29K | 0 | 0 | 0 | 72K | 145K | 150K | 135K | 10.68M |
| Current Ratio | 0.79x | 0.68x | 0.99x | 1.10x | 1.13x | 1.13x | 0.90x | 0.63x | 0.94x | 0.94x |
| Quick Ratio | 0.79x | 0.68x | 0.99x | 1.10x | 1.13x | 1.13x | 0.90x | 0.63x | 0.94x | 0.94x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 55.31 |
| Total Non-Current Liabilities | 164K | 621K | 1M | 3.35M | 8.96M | 8.8M | 7.94M | 6.49M | 4.72M | 3.39M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.37M |
| Capital Lease Obligations | 0 | 17K | 0 | 3.17M | 8.78M | 8.41M | 7.39M | 6.09M | 4.63M | 12.62M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 164K | 604K | 1M | 178K | 181K | 391K | 551K | 401K | 85K | 224K |
| Total Liabilities | 7.61M | 8.1M | 9.03M | 15.65M | 20.16M | 26.28M | 29.68M | 28.04M | 28.57M | 24.07M |
| Total Debt | 63K | 43K | 16K | 3.8M | 9.6M | 9.47M | 8.6M | 7.43M | 6.11M | 3.37M |
| Net Debt | -3.23M | -814K | -3.22M | -4.54M | 4.91M | 459K | -1.52M | 4.81M | -3.68M | -3.76M |
| Debt / Equity | 0.16x | - | 0.01x | 0.74x | 1.29x | 1.04x | 1.85x | - | 1.62x | 1.62x |
| Debt / EBITDA | - | - | 0.02x | - | 4.93x | 3.13x | - | - | 0.94x | -2.80x |
| Net Debt / EBITDA | - | - | -3.68x | - | 2.52x | 0.15x | - | - | -0.57x | -0.57x |
| Interest Coverage | - | - | - | - | - | 25.29x | - | -247.18x | 179.48x | - |
| Total Equity | 400K▲ 0% | -25K▼ 106.3% | 2.24M▲ 9052.0% | 5.1M▲ 127.8% | 7.43M▲ 45.7% | 9.1M▲ 22.5% | 4.64M▼ 49.0% | -1.9M▼ 141.0% | 3.77M▲ 298.2% | 4.38M▲ 0% |
| Equity Growth % | 68.07% | -106.25% | 9052% | 127.84% | 45.68% | 22.46% | -49.03% | -141.05% | 298.21% | 1965.22% |
| Book Value per Share | 0.04 | -0.00 | 0.16 | 0.43 | 0.51 | 0.64 | 0.34 | -0.14 | 0.26 | 0.32 |
| Total Shareholders' Equity | 400K | 3K | 2.24M | 5.1M | 7.43M | 9.1M | 4.64M | -1.9M | 3.77M | 4.28M |
| Common Stock | 11K | 11K | 12K | 13K | 13K | 14K | 14K | 14K | 14K | 14K |
| Retained Earnings | -69.35M | -70.83M | -70.7M | -72.89M | -72.53M | -71.98M | -77.32M | -84.59M | -79.89M | -80.4M |
| Treasury Stock | -1.25M | -1.25M | 0 | 0 | 0 | 0 | -74K | -708K | -708K | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 95K |
CSBR Cash Flow Statement
Champions Oncology, Inc. (CSBR) cash flow — operating, investing & free cash flow history
| Line item | Apr'17 | Apr'18 | Apr'19 | Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | Apr'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -2.84M | -1.23M | 1.86M | 2.9M | -1.68M | 6.5M | 3.96M | -6.14M | 7.39M | 7.39M |
| Operating CF Margin % | -18.43% | -6.06% | 6.88% | 9.04% | -4.1% | 13.23% | 7.34% | -12.24% | 12.97% | - |
| Operating CF Growth % | 55.98% | 56.83% | 251.88% | 56.02% | -157.87% | 486.5% | -39.13% | -255.17% | 220.35% | -315.22% |
| Net Income | -6.88M | -1.5M | 128K | -1.98M | 334K | 548K | -5.33M | -7.28M | 4.7M | -2.25M |
| Depreciation & Amortization | 168K | 360K | 606K | 825K | 1.18M | 1.63M | 2.25M | 1.87M | 1.64M | 1.45M |
| Stock-Based Compensation | 2.66M | 1M | 636K | 600K | 598K | 912K | 864K | 1.12M | 654K | 1.01M |
| Deferred Taxes | 24K | -44K | 71K | 560K | 49K | 0 | 1M | 0 | 0 | 0 |
| Other Non-Cash Items | 44K | 491K | 410K | 403K | 323K | 1.07M | 952K | 1.98M | 1.01M | -3.45M |
| Working Capital Changes | 1.15M | -1.53M | 11K | 2.49M | -4.17M | 2.34M | 4.23M | -3.82M | -621K | 7.73M |
| Change in Receivables | -986K | -1.6M | -531K | -670K | -2.27M | -2.82M | 1.31M | -1.99M | -1.44M | 4.5M |
| Change in Inventory | 404K | -27K | 571K | 1.04M | -1.1M | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -43K | 301K | 653K | 333K | -1.25M | 974K | 2.46M | 465K | -1.75M | -614K |
| Cash from Investing | -766K | -1.23M | -834K | -2.22M | -3.17M | -2.38M | -2.87M | -836K | -389K | -555K |
| Capital Expenditures | -766K | -1.23M | -834K | -2.22M | -3.28M | -2.38M | -2.87M | -836K | -389K | -578K |
| CapEx % of Revenue | 4.97% | 6.07% | 3.08% | 6.91% | 7.99% | 4.85% | 5.33% | 1.67% | 0.68% | - |
| Acquisitions | 0 | 3K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 112K | 0 | 0 | 0 | 0 | 23K |
| Cash from Financing | 4.32M | 13K | 1.2M | 4.42M | 1.2M | 207K | 11K | -527K | 170K | 86K |
| Debt Issued (Net) | -24K | -25K | -262K | -35K | -174K | 0 | 0 | -146K | -150K | -115K |
| Equity Issued (Net) | 1000K | 38K | 1000K | 1000K | 1000K | 207K | -74K | -634K | 320K | 237K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -74K | -634K | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 0 | 0 | 85K | 253K | 0 | -36K |
| Net Change in Cash | 710K▲ 0% | -2.44M▼ 443.5% | 2.23M▲ 191.5% | 5.11M▲ 128.8% | -3.65M▼ 171.6% | 4.32M▲ 218.2% | 1.11M▼ 74.3% | -7.5M▼ 775.1% | 7.17M▲ 195.6% | 3.92M▲ 0% |
| Free Cash Flow | -3.61M▲ 0% | -2.46M▲ 31.9% | 1.03M▲ 141.9% | 685K▼ 33.4% | -4.96M▼ 824.4% | 4.11M▲ 182.9% | 1.08M▼ 73.7% | -6.97M▼ 743.9% | 7M▲ 200.3% | 3.82M▲ 0% |
| FCF Margin % | -23.4% | -12.13% | 3.8% | 2.13% | -12.09% | 8.38% | 2.01% | -13.9% | 12.29% | 9.22% |
| FCF Growth % | 46.77% | 31.92% | 141.87% | -33.37% | -824.38% | 182.89% | -73.67% | -743.86% | 200.34% | 388.44% |
| FCF per Share | -0.33 | -0.22 | 0.07 | 0.06 | -0.34 | 0.29 | 0.08 | -0.51 | 0.49 | 0.49 |
| FCF Conversion (FCF/Net Income) | 0.41x | 0.83x | 14.55x | -1.39x | -4.64x | 11.86x | -0.74x | 0.84x | 1.57x | -1.70x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CSBR Key Ratios
Champions Oncology, Inc. (CSBR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -2157.99% | -787.2% | 11.57% | -57.05% | 5.78% | 6.63% | -77.7% | -532.46% | 503.05% | -56.54% |
| Return on Invested Capital (ROIC) | - | - | - | -214.32% | 4.26% | 4.16% | -52.66% | -172.28% | 242.22% | 242.22% |
| Gross Margin | 37.04% | 47.86% | 47.3% | 47.08% | 47.74% | 51.88% | 45.18% | 41.38% | 47.27% | 21.54% |
| Net Margin | -44.67% | -7.29% | 0.47% | -6.52% | 0.88% | 1.12% | -9.9% | -14.51% | 8.26% | -5.44% |
| Debt / Equity | 0.16x | - | 0.01x | 0.74x | 1.29x | 1.04x | 1.85x | - | 1.62x | 1.62x |
| Interest Coverage | - | - | - | - | - | 25.29x | - | -247.18x | 179.48x | - |
| FCF Conversion | 0.41x | 0.83x | 14.55x | -1.39x | -4.64x | 11.86x | -0.74x | 0.84x | 1.57x | -1.70x |
| Revenue Growth | 37.82% | 31.34% | 33.72% | 18.68% | 27.76% | 19.66% | 9.69% | -6.9% | 13.54% | -29.37% |
CSBR Frequently Asked Questions
Champions Oncology, Inc. (CSBR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Champions Oncology, Inc. (CSBR) reported $41.4M in revenue for fiscal year 2025. This represents a 1834% increase from $2.1M in 1996.
Champions Oncology, Inc. (CSBR) grew revenue by 13.5% over the past year. This is steady growth.
Champions Oncology, Inc. (CSBR) reported a net loss of $2.3M for fiscal year 2025.
Dividend & Returns
Champions Oncology, Inc. (CSBR) has a return on equity (ROE) of 503.0%. This is excellent, indicating efficient use of shareholder capital.
Champions Oncology, Inc. (CSBR) generated $3.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More CSBR
Champions Oncology, Inc. (CSBR) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates